KDM6B and ovarian cancer: It was further found that the molecular mechanism of the above drugs-loaded nanoparticles may be through preventing JMJD3 (epigenetic regulator) binding with H3K27me3 (suppressor of transcription), thereby protecting the lysine trimethylation of H3K27me3 and antagonizing the effect of JMJD3, finally promoting the differentiation of ovarian cancer stem cells by reducing the transcription of the oncogene HER2.